CERT — Certara, Inc.

Certara Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: $104.6 million, up 10% year-over-year.
• Adjusted EBITDA: $35.2 million, with a margin of 34%.
• Bookings: $96.6 million, a 1% increase year-over-year; trailing 12-month bookings at $471.4 million, up 12%.
• Software Revenue: $43.8 million, a 22% increase; organic growth at 6%.
• Services Revenue: $60.8 million, up 3% year-over-year.
• Net Income: $1.5 million, compared to a net loss of $1.4 million in Q3 2024.
• Adjusted EPS: $0.14, up from $0.13 in the prior year.

2. Strategic Updates and Business Highlights

• Continued investment in R&D, increasing to 10% of revenue, with a 24% year-over-year growth in R&D spending.
• Successful product launches, including Pinnacle 21 Enterprise, Phoenix Cloud, and CertaraIQ, which are expected to enhance software growth.
• Positive reception of new products, particularly in the QSP (Quantitative Systems Pharmacology) area, which is becoming a key growth driver.
• The Chemaxon acquisition is performing well, contributing $5.6 million in revenue and on track for corporate average margins by year-end.

3. Forward Guidance and Outlook

• Revenue guidance narrowed to $415 million to $420 million for 2025, reflecting 8% to 9% growth.
• Adjusted EBITDA margin guidance raised to around 32%.
• Adjusted EPS expected in the range of $0.45 to $0.47.
• Anticipation of continued cautious spending behavior among Tier 1 customers into Q4, impacting bookings.

4. Bad News, Challenges, or Points of Concern

• Bookings Decline: Notable slowdown in Tier 1 services bookings, with cautious spending and delayed decision-making affecting revenue.
• Regulatory Services: Decline in regulatory services bookings, with some customers facing hesitancy in decision-making.
• Market Conditions: Ongoing macroeconomic uncertainties affecting large pharma customers, leading to a cautious outlook for 2026.
• Organic Bookings: Excluding Chemaxon, organic bookings declined by 4% year-over-year.

5. Notable Q&A Insights

• Management acknowledged a slowdown in decision-making among Tier 1 customers, with expectations for continued hesitancy into Q4.
• There is cautious optimism regarding a stabilizing macro environment, which could positively impact growth in 2026.
• The company is seeing strong performance in Tier 2 and Tier 3 services, contrasting with challenges faced by Tier 1 customers.
• Concerns about potential impacts from government shutdowns on FDA operations were addressed, with management expressing confidence in a resolution that would not significantly affect operations.

Overall, Certara's Q3 2025 results reflect solid revenue growth and strategic advancements, though challenges in Tier 1 customer spending and regulatory services present notable headwinds as the company looks toward 2026.